Invesco Ltd. Reduces Position in Johnson & Johnson $JNJ

Invesco Ltd. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 24.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,016,955 shares of the company’s stock after selling 4,457,751 shares during the period. Invesco Ltd. owned 0.58% of Johnson & Johnson worth $2,141,090,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. GFG Capital LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at about $48,000. Vermillion & White Wealth Management Group LLC raised its stake in Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after acquiring an additional 150 shares during the last quarter. Finally, Pandora Wealth Inc. acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $65,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $205.38 on Wednesday. The company has a market cap of $494.82 billion, a P/E ratio of 19.82, a P/E/G ratio of 2.19 and a beta of 0.36. The business has a fifty day simple moving average of $192.54 and a 200-day simple moving average of $174.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $207.81. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on JNJ shares. Raymond James Financial upped their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Bank of America raised their price objective on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Finally, Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a research report on Monday, October 20th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $202.10.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.